全文获取类型
收费全文 | 876篇 |
免费 | 42篇 |
出版年
2022年 | 1篇 |
2021年 | 7篇 |
2020年 | 7篇 |
2019年 | 7篇 |
2018年 | 12篇 |
2017年 | 9篇 |
2016年 | 19篇 |
2015年 | 34篇 |
2014年 | 29篇 |
2013年 | 39篇 |
2012年 | 68篇 |
2011年 | 58篇 |
2010年 | 28篇 |
2009年 | 32篇 |
2008年 | 64篇 |
2007年 | 65篇 |
2006年 | 55篇 |
2005年 | 54篇 |
2004年 | 51篇 |
2003年 | 57篇 |
2002年 | 70篇 |
2001年 | 21篇 |
2000年 | 4篇 |
1999年 | 11篇 |
1998年 | 8篇 |
1997年 | 11篇 |
1996年 | 11篇 |
1995年 | 7篇 |
1994年 | 7篇 |
1993年 | 7篇 |
1992年 | 3篇 |
1991年 | 7篇 |
1990年 | 7篇 |
1989年 | 4篇 |
1988年 | 3篇 |
1987年 | 2篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1984年 | 3篇 |
1982年 | 1篇 |
1981年 | 5篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1977年 | 2篇 |
1976年 | 4篇 |
1975年 | 7篇 |
1973年 | 6篇 |
1971年 | 1篇 |
1970年 | 2篇 |
1963年 | 1篇 |
排序方式: 共有918条查询结果,搜索用时 15 毫秒
1.
Kazuma Nakano Akino Shiroma Makiko Shimoji Hinako Tamotsu Noriko Ashimine Shun Ohki Misuzu Shinzato Maiko Minami Tetsuhiro Nakanishi Kuniko Teruya Kazuhito Satou Takashi Hirano 《Human cell》2017,30(3):149-161
PacBio RS II is the first commercialized third-generation DNA sequencer able to sequence a single molecule DNA in real-time without amplification. PacBio RS II’s sequencing technology is novel and unique, enabling the direct observation of DNA synthesis by DNA polymerase. PacBio RS II confers four major advantages compared to other sequencing technologies: long read lengths, high consensus accuracy, a low degree of bias, and simultaneous capability of epigenetic characterization. These advantages surmount the obstacle of sequencing genomic regions such as high/low G+C, tandem repeat, and interspersed repeat regions. Moreover, PacBio RS II is ideal for whole genome sequencing, targeted sequencing, complex population analysis, RNA sequencing, and epigenetics characterization. With PacBio RS II, we have sequenced and analyzed the genomes of many species, from viruses to humans. Herein, we summarize and review some of our key genome sequencing projects, including full-length viral sequencing, complete bacterial genome and almost-complete plant genome assemblies, and long amplicon sequencing of a disease-associated gene region. We believe that PacBio RS II is not only an effective tool for use in the basic biological sciences but also in the medical/clinical setting. 相似文献
2.
3.
4.
5.
6.
7.
Takeshi Nishijima Shigeko Yashiro Katsuji Teruya Yoshimi Kikuchi Naomichi Katai Shinichi Oka Hiroyuki Gatanaga 《PloS one》2015,10(9)
Objective
To investigate whether routine eye screening by an ophthalmologist in patients with HIV-1 infection is clinically useful.Methods
A single-center, retrospective study in Tokyo, Japan. HIV-1-infected patients aged over 17 years who visited our clinic for the first time between January 2004 and December 2013 and underwent full ophthalmologic examination were enrolled. At our clinic, ophthalmologic examination, including dilated retinal examination by indirect ophthalmoscopy was routinely conducted by ophthalmologists on the first visit. The prevalence of ophthalmologic diseases and associated factors including the existence of ocular symptoms were analyzed.Results
Of the 1,515 study patients, cytomegalovirus retinitis (CMV-R) was diagnosed in 24 (2%) patients, HIV retinopathy (HIV-R) in 127 (8%), cataract in 31 (2%), ocular syphilis in 4 (0.3%), and uveitis with unknown cause in 8 (0.5%). Other ocular diseases were diagnosed in 14 patients. The CD4 count was <200 /μL in all CMV-R cases and 87% of HIV-R. The prevalence of any ocular diseases, CMV-R, and HIV-R in patients with CD4 <200 /μL were 22%, 3%, and 15%, respectively, whereas for those with CD4 ≥200 /μL were 5%, 0%, and 2%, respectively. No ocular symptoms were reported by 71% of CMV-R cases and 82% of patients with any ocular diseases.Conclusions
Routine ophthalmologic screening is recommended for HIV-1-infected patients with CD4 <200 /μL in resource-rich settings based on the high prevalence of ocular diseases within this CD4 count category and because most patients with ocular diseases, including those with CMV-R, were free of ocular symptoms. 相似文献8.
Koji Sugano Toru Okuyama Shinsuke Iida Hirokazu Komatsu Takashi Ishida Shigeru Kusumoto Megumi Uchida Tomohiro Nakaguchi Yosuke Kubota Yoshinori Ito Kazuhisa Takahashi Tatsuo Akechi 《PloS one》2015,10(8)
Background
Decision-making capacity to provide informed consent regarding treatment is essential among cancer patients. The purpose of this study was to identify the frequency of decision-making incapacity among newly diagnosed older patients with hematological malignancy receiving first-line chemotherapy, to examine factors associated with incapacity and assess physicians’ perceptions of patients’ decision-making incapacity.Methods
Consecutive patients aged 65 years or over with a primary diagnosis of malignant lymphoma or multiple myeloma were recruited. Decision-making capacity was assessed using the Structured Interview for Competency and Incompetency Assessment Testing and Ranking Inventory-Revised (SICIATRI-R). Cognitive impairment, depressive condition and other possible associated factors were also evaluated.Results
Among 139 eligible patients registered for this study, 114 completed the survey. Of these, 28 (25%, 95% confidence interval [CI]: 17%-32%) were judged as having some extent of decision-making incompetency according to SICIATRI-R. Higher levels of cognitive impairment and increasing age were significantly associated with decision-making incapacity. Physicians experienced difficulty performing competency assessment (Cohen’s kappa -0.54).Conclusions
Decision-making incapacity was found to be a common and under-recognized problem in older patients with cancer. Age and assessment of cognitive impairment may provide the opportunity to find patients that are at a high risk of showing decision-making incapacity. 相似文献9.
10.
Tohru Tanigawa Rei Shibata Kazuhisa Kondo Nobuyuki Katahira Takahiro Kambara Yoko Inoue Hiroshi Nonoyama Yuichiro Horibe Hiromi Ueda Toyoaki Murohara 《PloS one》2015,10(9)
Obesity-related complications are associated with the development of age-related hearing impairment. β-Conglycinin (β-CG), one of the main storage proteins in soy, offers multiple health benefits, including anti-obesity and anti-atherosclerotic effects. Here, to elucidate the potential therapeutic application of β-CG, we investigated the effect of β-CG on age-related hearing impairment. Male wild-type mice (age 6 months) were randomly divided into β-CG-fed and control groups. Six months later, the body weight was significantly lower in β-CG-fed mice than in the controls. Consumption of β-CG rescued the hearing impairment observed in control mice. Cochlear blood flow also increased in β-CG-fed mice, as did the expression of eNOS in the stria vascularis (SV), which protects vasculature. β-CG consumption also ameliorated oxidative status as assessed by 4-HNE staining. In the SV, lipofuscin granules of marginal cells and vacuolar degeneration of microvascular pericytes were decreased in β-CG-fed mice, as shown by transmission electron microscopy. β-CG consumption prevented loss of spiral ganglion cells and reduced the frequencies of lipofuscin granules, nuclear invaginations, and myelin vacuolation. Our observations indicate that β-CG ameliorates age-related hearing impairment by preserving cochlear blood flow and suppressing oxidative stress. 相似文献